Why the IMPACCT Real World Evidence Summit Europe Was Your Must-Attend Meeting for 2024!
Following DARWIN EU announcing their aim to deliver 150 RWE studies by 2025, and the 2022 European Health Data Space (EHDS) regulation, the drug development industry is coming to an exciting inflection point.
As a sister meeting to the established 11th IMPACCT: Real World Evidence Summit US, the IMPACCT: Real World Evidence Summit Europe was dedicated to uniting the European community by leveraging real world data in clinical research to facilitate evidence-based decision-making, developing more efficient research protocols, and support regulatory submissions.
Diving from using natural history studies to characterise patient populations in rare diseases to conducting safety studies in phase IV, the Summit was your only opportunity to learn from over 16 experts across 3 days on their practical strategies and lessons learned to integrate real world evidence into their clinical research.
Your Biopharma Peers Experienced:
Expert case studies uncovering methods for database aggregation including linkage and harmonisation strategies to better support data analysis workflows and ensure data integrity
Practical insights into different disease areas and understand the nuances involved in generating and leveraging evidence for cancer through ophthalmic and rare diseases
Exchanging challenges, inspiring solutions with leading industry experts across dedicated speed-networking sessions as well and assess the exciting technologies used by industry leaders
A deep dive into strategies to implement real world evidence to support trial design starting from patient selection through to accelerating clinical trial timelines by enhancing research protocols
Meetings and networking with selected CROs, data providers, analytics providers, and consultants to hear their latest platforms that would optimize your workflows
Hear what your peers had to say about the sister meeting:
“Small enough conference to have meaningful discussions, most of the sessions were focused on thought leadership in the space.”
EVP North American Sales, BC Platforms
“Good size of attendees to allow for productive, engaging discussions. Diversity of presenters and attendees including regulators, HTA, CRO partners, Pharma/biotech etc.”
Executive Director & Team Lead - Oncology Worldwide Real-world Evidence & Health Economics, Outcomes Research, Eisai
“Learning about different approaches to using RWE for regulatory and clinical purposes.”
Senior Manager, Alexion
Who Would You Have Met:
